Publications

2016 cardiometabolic

Clinical and Cost-Effectiveness of Insulin Delivery with V-Go® Disposable Insulin Delivery Device Versus Multiple Daily Injections in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin

Endocr Pract.

2016; 22(6): 726-35

2016 cardiometabolic

Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator.

Diabetes Technol. Ther

2016; 18(9): 574–585

2015 cardiometabolic

V-Go Insulin Delivery System versus Multiple Daily Insulin Injections for Patients with Uncontrolled Type 2 Diabetes Mellitus

J Diabetes Sci Technol.

2015; 9(5): 1111-16

2015 cardiometabolic

Use of V-Go® Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System

Diabetes Ther.

2015; 6(4): 531-45

2015 cardiometabolic

Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents.

Diabetes Care

2015; 38(12): 2274-81

2015 cardiometabolic

Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.

Diabetes Care

2015; 38(12): 2266-73

2013 cardiometabolic

Device factors affecting pulmonary delivery of dry powders.

Ther. Deliv.

2013; 4(8): 939-49

2012 cardiometabolic

Technosphere Insulin Effectively Controls Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus.

Diabetes Technol. Ther.

2012;14: 9‍97-1‍001

2012 cardiometabolic

The V-Go Insulin Delivery Device Used in Clinical Practice: Patient Perception and Retrospective Analysis of Glycemic Control

Endocr Pract.

2012; 18(5): 660-67

2012 cardiometabolic

Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: A randomized trial.

Diabetes Obesity Metab.

2012; 14: 163-173.

2011 cardiometabolic

Insulin Lung Deposition and Clearance Following Technosphere^® Insulin Inhalation Powder Administration

Pharm. Res.

2011; 28; 2‍157–2‍164

2008 cardiometabolic

A Delineation of Diketopiperazine Self-Assembly Processes: Understanding the Molecular Events Involved in N^ϵ-(Fumaroyl) diketopiperazine of l-Lys (FDKP) Interactions.

Mol. Pharmaceutics.

2008; 5(2): 294–315

< Previous … Next >

Expanding Patient Choice in Diabetes Care: Reducing Access Barriers to Inhaled Insulin

Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry

Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes

Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living with Type 1 Diabetes

Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study

Role of Ultra-Rapid Acting Insulin in Managing Diabetes

30 Years of Developing Inhaled Insulin

Dosing Afrezza: It's Not that Complicated

Unmet Needs in Insulin-Treated Diabetes Management

Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review

Impact of Inhaled Insulin Therapy on Hypoglycemia

Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations

Clinical and Cost-Effectiveness of Insulin Delivery with V-Go® Disposable Insulin Delivery Device Versus Multiple Daily Injections in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin

Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator.

V-Go Insulin Delivery System versus Multiple Daily Insulin Injections for Patients with Uncontrolled Type 2 Diabetes Mellitus

Use of V-Go® Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System

Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents.

Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.

Device factors affecting pulmonary delivery of dry powders.

Technosphere Insulin Effectively Controls Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus.

The V-Go Insulin Delivery Device Used in Clinical Practice: Patient Perception and Retrospective Analysis of Glycemic Control

Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: A randomized trial.

Insulin Lung Deposition and Clearance Following Technosphere^® Insulin Inhalation Powder Administration

A Delineation of Diketopiperazine Self-Assembly Processes: Understanding the Molecular Events Involved in N^ϵ-(Fumaroyl) diketopiperazine of l-Lys (FDKP) Interactions.

Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases

Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Inhaled, Nebulized Clofazimine for the Treatment of Pulmonary Nontuberculous Mycobacteria Disease Offers the Prospect of Convenient Dosing and Prolonged Activity

Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection

Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections

Now FDA Approved:
Furoscix ReadyFlow™

(furosemide injection)

Publications

Expanding Patient Choice in Diabetes Care: Reducing Access Barriers to Inhaled Insulin

Experiences With Inhaled Insulin in a Real-World Sample of Adults With Type 1 Diabetes in the T1D Exchange Registry

Inhaled Insulin Dosing in a Randomized Trial in Adults With Type 1 Diabetes

Inhaled Technosphere Insulin Reduces Postmeal Glucose Excursion in Youth Living with Type 1 Diabetes

Inhaled Technosphere Insulin in Children with Diabetes: The INHALE-1 Extension Study

Role of Ultra-Rapid Acting Insulin in Managing Diabetes

30 Years of Developing Inhaled Insulin

Dosing Afrezza: It's Not that Complicated

Unmet Needs in Insulin-Treated Diabetes Management

Pulmonary Safety and Clinical Considerations for Inhaled Insulin: A Comprehensive Review

Impact of Inhaled Insulin Therapy on Hypoglycemia

Potential Applications of Inhaled Insulin in Diabetic Ketoacidosis Prevention and During Exercise: Two Case Presentations

Clinical and Cost-Effectiveness of Insulin Delivery with V-Go® Disposable Insulin Delivery Device Versus Multiple Daily Injections in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin

Improving Efficacy of Inhaled Technosphere Insulin (Afrezza) by Postmeal Dosing: In-silico Clinical Trial with the University of Virginia/Padova Type 1 Diabetes Simulator.

V-Go Insulin Delivery System versus Multiple Daily Insulin Injections for Patients with Uncontrolled Type 2 Diabetes Mellitus

Use of V-Go® Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System

Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents.

Inhaled Technosphere Insulin Compared With Injected Prandial Insulin in Type 1 Diabetes: A Randomized 24-Week Trial.

Device factors affecting pulmonary delivery of dry powders.

Technosphere Insulin Effectively Controls Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus.

The V-Go Insulin Delivery Device Used in Clinical Practice: Patient Perception and Retrospective Analysis of Glycemic Control

Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: A randomized trial.

Insulin Lung Deposition and Clearance Following Technosphere® Insulin Inhalation Powder Administration

A Delineation of Diketopiperazine Self-Assembly Processes: Understanding the Molecular Events Involved in Nϵ-(Fumaroyl) diketopiperazine of l-Lys (FDKP) Interactions.

Safety and Pharmacokinetic Data for Inhaled Administration of Nintedanib Dry Powder Inhalation for Treatment of Pulmonary Fibrotic Diseases

Preclinical Studies of Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Clofazimine Inhalation Suspension: A Novel Formulation for the Treatment of Pulmonary Nontuberculous Mycobacterial Disease

Inhaled, Nebulized Clofazimine for the Treatment of Pulmonary Nontuberculous Mycobacteria Disease Offers the Prospect of Convenient Dosing and Prolonged Activity

Clofazimine Inhalation Suspension Demonstrates Promising Toxicokinetics in Canines for Treating Pulmonary Nontuberculous Mycobacteria Infection

Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections

Now FDA Approved: Furoscix ReadyFlow™

(furosemide injection)

Insulin Lung Deposition and Clearance Following Technosphere^® Insulin Inhalation Powder Administration

A Delineation of Diketopiperazine Self-Assembly Processes: Understanding the Molecular Events Involved in N^ϵ-(Fumaroyl) diketopiperazine of l-Lys (FDKP) Interactions.

Now FDA Approved:
Furoscix ReadyFlow™